FMTX Forma Therapeutics Holdings, Inc.

Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for the treatment of hematologic diseases and cancers. Its product pipeline consists of FT-4202 for the treatment of sickle cell disease and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company was founded by Michael A. Foley in December 2011 and is headquartered in Watertown, MA.

$26.36  +0.40 (1.54%)
As of 06/24/2021 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/19/2020
Outstanding shares:  47,372,658
Average volume:  386,549
Market cap:   $1,229,794,202
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    34633R104
ISIN:        US34633R1041
Sedol:      BLB2Y98
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.03
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy